Keytruda unlikely to face pushback from clinicians in HCC

Despite a Phase III miss for Merck & Co.'s Keytruda pembrolizumab to treat hepatocellular carcinoma, enthusiasm for the PD-1 inhibitor in the indication remains, according to comments made Sunday at the American Society of Clinical Oncology meeting in Chicago.

In November, FDA granted accelerated approval to Keytruda from Merck & Co. Inc. (NYSE:MRK) to treat HCC in patients

Read the full 579 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE